Caroline is currently in the middle of her first cycle of the Naxitamab + Tipifarnib Clinical Trial. She completed the infusion portion on Friday, 4/24, but had a difficult recovery and ended up back at the hospital the following Monday, 4/27. After receiving supportive medications, fluids, and a few adjustments to her daily medications, she was able to turn the corner—and even made it back to school the very next day.
She is now continuing the oral inhibitor medication (Tipifarnib) twice daily at home and was seen in clinic again this morning. Aside from some nausea, she has been doing really well.
Caroline will return to clinic next week for continued monitoring, with her next cycle currently scheduled to begin on 5/18.
Thank you for your patience with the delay in updates, and thank you, as always, for your continued prayers and support.
All the best,Team Lantz
#carolinestrong
#ftgf
